510(k) Exemption for Class II Clinical Toxicology Tests: Compliance Obligations That Remain

What Did FDA Just Change for Clinical Toxicology Test Systems?

On October 6, 2026, FDA published a final order in the Federal Register (document 2026-20448) exempting certain class II clinical toxicology test systems from premarket notification, with limitations. Confirm the effective date in the order's DATES section before relying on it. If your device is within a covered generic device type and meets every limitation the order sets, you may market it in the United States without a cleared 510(k). If it does not, the 510(k) requirement still applies.

I want to say up front what the lesson is, because it is easy to misread an exemption as a relaxation of the whole regulatory burden. An exemption from 510(k) removes one submission. It does not remove the device from FDA oversight, and it does not remove the quality system, the registration, the complaint handling, or the labeling obligations that sit around that submission. Companies that treat "exempt" as "unregulated" are the ones who end up with inspection observations.

The source for this article is the Federal Register order itself: Medical Devices; Exemptions From Premarket Notification: Class II Devices; Certain Clinical Toxicology Test Systems. I recommend reading the order's list of devices and its stated limitations directly, because the exact product scope is what decides whether your device benefits. This is a compliance-framework article, not a coverage guide. It describes how the exemption works and the obligations that remain after it. It does not list the covered 21 CFR Part 862 generic device types, because I have not verified that list section by section against the order, and the order's list controls. Do not infer coverage from this article. Confirm that your device's regulation number appears in the order before you treat the device as exempt.

What Is the Legal Basis for a Class II 510(k) Exemption?

Section 510(m) of the Federal Food, Drug, and Cosmetic Act lets FDA exempt a class II device from the 510(k) requirement if FDA determines that a 510(k) is not necessary to provide reasonable assurance of the device's safety and effectiveness. The statute sets a process that includes a Federal Register notice and an opportunity for public comment before a final order. This October 2026 order is the final order for the clinical toxicology devices it names. Check the order for the proposing notice and docket number.

One thing follows from that process: class II stays class II. The device classification regulation, including any special controls, still applies. What changed is the premarket pathway, not the risk classification.

Clinical toxicology test systems are classified in 21 CFR Part 862, Subpart D. These are in vitro diagnostic devices intended to measure drugs, alcohol, and related substances in human specimens for clinical use. The order addresses certain class II generic types within that subpart.

What Does "Subject to Certain Limitations" Mean?

This phrase is where most of the practical risk lives. The limitations on exemptions for clinical chemistry and toxicology devices appear in 21 CFR 862.9, and the order applies them to the device types it names. This article does not paraphrase those conditions, because the exact wording, including any limits specific to a device type, is what decides coverage. Read 21 CFR 862.9 and the order's limitation language in full. Pull the order, find your generic device type and its 21 CFR 862 regulation number, and read the limitation language that applies to that type.

In my view, the cleanest way to run this is a short written exemption determination, signed and filed in your design history or technical documentation. It should state the regulation number, the product code, the intended use statement, the technology, and how each limitation was checked. If an FDA investigator later asks why you did not file a 510(k), that document is your answer.

Who Benefits and Who Does Not?

Situation	Likely effect of the order	What to verify
New toxicology test system in a covered generic type, same intended use and technology as existing devices	No 510(k) needed to market in the U.S.	Regulation number, product code, and each 21 CFR 862.9 limitation
Existing cleared device in a covered type	Prior clearance stays valid. Whether a future change needs a new 510(k) depends on whether the changed device still meets the exemption's limitations	Whether the change keeps the device inside the limitations
Device with a new intended use, new claims, or new fundamental technology	Exemption may not apply, so a 510(k) or other pathway may still be required	Whether the device still fits the generic type
Device in a toxicology type not named in the order	No change	Whether FDA has exempted that type under a separate action
Manufacturer selling in the EU, Canada, or other markets	No change to those markets' requirements	Local premarket and conformity assessment rules

The last row matters for anyone with an international plan. A U.S. 510(k) exemption has no effect on EU IVDR conformity assessment, on Health Canada licensing, or on any other market's premarket review. If you were using a U.S. clearance as supporting evidence for those markets, you may need to build that evidence another way.

What Obligations Remain After the 510(k) Exemption?

Keep this list in front of the team. A 510(k) exemption leaves the following in place.

Establishment registration and device listing. 21 CFR Part 807 still applies. You register your establishment and list the device, and your listing should reflect that the device is exempt from 510(k).

Quality system requirements. 21 CFR Part 820 still applies unless the device is separately exempt from it, which clinical toxicology test systems generally are not. FDA's Quality Management System Regulation (final rule published February 2, 2024, at 89 FR 7496, with an effective date of February 2, 2026) incorporates ISO 13485:2016 by reference, so for a toxicology test manufacturer the practical expectation is a QMS that maps to ISO 13485. Design and development controls, including verification and validation of the assay's analytical performance, remain your responsibility. For more on this, see our overview of design controls.

Labeling. 21 CFR Part 801, and for in vitro diagnostics 21 CFR 809.10, govern labeling. Your package insert, performance claims, and any limitations on specimen type need to be supported by data you hold.

Medical device reporting. 21 CFR Part 803 requires you to report deaths, serious injuries, and certain malfunctions. A wrong toxicology result that leads to a clinical decision can create reportable events.

Corrections and removals. 21 CFR Part 806 requires reports of certain corrections and removals undertaken to reduce a risk to health.

Special controls. If the classification regulation for your generic type lists special controls, those remain the requirements your design must meet, even though no one at FDA will review your 510(k) against them first.

A useful way to say it: a 510(k) exemption changes who checks your work before launch, and it leaves you fully responsible for the work itself.

How Should a Manufacturer Respond This Week?

Here is the order I would work in, and I would not skip steps.

Read the order and identify your device. Match your product to the generic type and regulation number in the order. Confirm the product code in FDA's classification database.
Check the limitations. Walk through 21 CFR 862.9 and any limitation specific to your generic type. Document each answer.
Write the exemption determination. Record the conclusion, the date, the reviewer, and the evidence. Put it under document control.
Update registration and listing. Make sure your device listing under 21 CFR Part 807 is accurate, including the premarket pathway.
Re-check your change control procedure. Many QMS procedures say "assess whether a change requires a new 510(k)." That decision tree now has a new branch for exempt devices. The question becomes whether the change keeps the device within the exemption's limits.
Review your labeling and claims. If you intended to add a claim that would have been tested in a 510(k), confirm that the claim is still within the generic type's intended use.
Brief your distributors and customers. Some hospital laboratories and distributors ask for a 510(k) number as a purchasing requirement. Prepare a short statement explaining the exemption and the regulation number.
Plan for other markets. If you rely on the U.S. clearance elsewhere, confirm what the other regulator expects.

If your company has been preparing a 510(k) for a covered device, stop and decide deliberately whether to withdraw or continue. Some companies will keep a clearance because customers value it, and others will redirect that budget into analytical validation. Either is defensible if the decision is documented. For background on how the premarket pathway and the QMS interact, see how ISO 13485 supports your FDA 510(k) submission, and the 510(k) overview.

What Mistakes Do I Expect to See?

Watch for four patterns:

Assuming coverage by analogy. The exemption is tied to specific generic device types, so a nearby type may not be included.
Letting a feature change quietly push the device outside the limitations. Examples are adding a new specimen matrix or a new claim for a different clinical use.
Dropping design control rigor because no one is reviewing a submission.
Forgetting that CLIA categorization is a separate system. Whether a test is waived, moderate complexity, or high complexity under the Clinical Laboratory Improvement Amendments is decided separately, and a 510(k) exemption does not change it. FDA makes that categorization, and it affects which laboratories can run your test and what your labeling and customer claims must support. Do not tell customers that an exempt test is waived, or that it is easier to run, unless the categorization says so.

Without the premarket review, your design history file is the only place the performance evidence lives. Treat it as if a reviewer will read it, because an investigator may.

Where Can You Get Help?

If you are unsure whether your device is covered, or whether your QMS is ready to carry a product without a 510(k) behind it, the contact page is the place to start. I am happy to look at the generic type, the limitations, and the paperwork with you.

The honest bottom line: the order removes a submission, and your quality system now has to carry the full weight of showing the device is safe and works.

Last updated: 2026-10-07

Frequently Asked Questions

Is the 510(k) exemption for clinical toxicology test systems already in effect?

Yes. FDA's final order, published in the Federal Register on October 6, 2026 (document 2026-20448), states the exemption is immediately in effect for the covered class II devices, subject to the stated limitations.

Does a 510(k) exemption mean the device is no longer regulated by FDA?

No. The device remains class II. Establishment registration and listing (21 CFR Part 807), the quality system requirements (21 CFR Part 820, which incorporates ISO 13485:2016 by reference), labeling, medical device reporting (Part 803), and corrections and removals reporting (Part 806) still apply.

How do I know whether my toxicology test qualifies for the exemption?

Identify your generic device type and regulation number in 21 CFR Part 862, Subpart D, confirm it is named in the order, and check the limitations in the order and in 21 CFR 862.9. Document the conclusion in a signed exemption determination.

Do I need to give up an existing 510(k) clearance for a covered device?

No. An existing clearance does not need to be surrendered. Whether to keep referencing it is a business decision, and some customers and other markets may still value it.

Does the U.S. exemption affect EU or Canadian requirements?

No. The order applies only to U.S. premarket notification. EU IVDR conformity assessment, Health Canada licensing, and other markets' rules are unchanged.